Corporation
AstraZeneca Canada Inc.
- Meetings this Parliament
- 63
- With MPs
- 19
- Since Nov 2021
- 134
- Active registrations
- 1
Most recent reported meeting: Aug 28, 2026.
Lobbying by AstraZeneca Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingWho they meet
Since the current Parliament opened.
MPs
- Marjorie Michel Liberal 4
- Maggie Chi Liberal 2
- Karim Bardeesy Liberal 1
- Aslam Rana Liberal 1
- Raquel Dancho Conservative 1
- Maxime Blanchette-Joncas Bloc Québécois 1
- Matt Jeneroux Liberal 1
- Ali Ehsassi Liberal 1
- Karina Gould Liberal 1
- François-Philippe Champagne Liberal 1
- Linda Lapointe Liberal 1
- Mélanie Joly Liberal 1
Institutions
- Innovation, Science and Economic Development Canada (ISED)19
- Health Canada (HC)17
- House of Commons11
- Finance Canada (FIN)9
- Treasury Board Of Canada Secretariat (TBS)7
- Privy Council Office (PCO)6
- Prime Minister's Office (PMO)5
- Global Affairs Canada (GAC)5
Registrations in effect
In-house (corporation) In effect since May 11, 2026
Filed by Gaby Bourbara, President
Lobbyists
- Alex Romanovschi · Vice President, Scientific Affairs
- Carlo Mastrangelo · Head - Corporate Communications - Corporate Affairs Canada
- Deb Wong · Director, Payer Engagement
- Denise Lacombe · Head of Legal
- Gena Restivo · VP, Corporate Affairs & Sustainability
- Heather McDonald · Vice President, Market Access and Pricing
- Isabelle Gagnon · Lead - Federal Government Affairs
- Jon Feairs · Director, Government Affairs & Public Policy
- Noel Saraza · Senior Manager, Payer Relations
- Pascal Soriot · Chief Executive
- Tharany Ganesh · Head of Regulatory Affairs
Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Canada Economic Development for Quebec Regions, Canada Foundation for Innovation, Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Canadian Northern Economic Development Agency (CanNor), Competition Bureau Canada (COBU), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), International Development Research Centre (IDRC), National Defence (DND), National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (14)Hide details
- Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV
- Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries
- Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework
- Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
- Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
- Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
- Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
- Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
- Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
- Annual federal Budgets and Budget updates relating to the biopharmaceutical industry.
- Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.
Registration 957438-15042-67. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Gaby Bourbara (91), Kiersten Combs (43).
-
Reported by Gaby Bourbara · In-house (corporation)
- Varun Srivatsan · Director of Policy, Finance Canada (FIN)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Gaby Bourbara · In-house (corporation)
- François-Philippe Champagne · Minister of Finance and National Revenue, Finance Canada (FIN)
- Jean-Philippe Arseneau · Chief of Staff, Finance Canada (FIN)
- Varun Srivatsan · Director of Policy, Finance Canada (FIN)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Gaby Bourbara · In-house (corporation)
- Eric Costen · Deputy Secretary to the Cabinet (Operations), Privy Council Office (PCO)
- Greg Reade · Assistant Secretary to the Cabinet for Economic and Regional Development, Privy Council Office (PCO)
- Olesia Bissett · Analyst, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
-
Reported by Gaby Bourbara · In-house (corporation)
- Kaili Levesque · ADM, ISED Deputy to Secretary of State, Innovation, Science and Economic Development Canada (ISED)
- Stephanie Tanton · Assistance Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
-
Reported by Gaby Bourbara · In-house (corporation)
- Eric Costen · Deputy Secretary to the Cabinet (Operations), Privy Council Office (PCO)
- Olesia Bissett · Analyst, Privy Council Office (PCO)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
-
Reported by Gaby Bourbara · In-house (corporation)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Raquel Dancho · Member of Parliament
- David Bredin · Director of Parliamentary Affairs, House of Commons
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Gaby Bourbara · In-house (corporation)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Mark Carney · Prime Minister, Prime Minister's Office (PMO)
- Marc-André Blanchard · Chief of Staff, Prime Minister's Office (PMO)
- Eric Costen · Deputy Secretary to the Cabinet (Operations), Privy Council Office (PCO)
- Yash Nanda · Policy Advisor, Prime Minister's Office (PMO)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
-
Reported by Gaby Bourbara · In-house (corporation)
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
and 10 moreShow fewer
- Justine Frame · Policy Advisor, Health Canada (HC)
- Fatouma Bah · Policy Advisor, Health Canada (HC)
- Supriya Sharma · Acting Assistant Deputy Minister, Health Canada (HC)
- Scott Lohnes · Senior Advisor, Health Canada (HC)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Annahat Kochhar · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Greg Reade · Assistant Secretary to the Cabinet for Economic and Regional Development, Privy Council Office (PCO)
- Sachelle Magloire-Prosper · Director of Operations, Privy Council Office (PCO)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
-
Reported by Gaby Bourbara · In-house (corporation)
- Samir Khan · Associate Executive Director, Health Canada (HC)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
and 6 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
- Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Aslam Rana · MP
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Arianne Reza · Deputy Minister, Public Services and Procurement Canada (PSPC)
- Joelle Paquette · Associate Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Gaby Bourbara · In-house (corporation)
- Marc-André Blanchard · Chief of Staff, Prime Minister's Office (PMO)
- Yash Nanda · Senior Policy Advisor, Prime Minister's Office (PMO)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
-
Reported by Gaby Bourbara · In-house (corporation)
- Dan Mazier · Member of Parliament
- Ethan Bubba · Parliamentary Assistant, House of Commons
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Gaby Bourbara · In-house (corporation)
- Janice Charette · Chief Trade Negotiator to the US, Global Affairs Canada (GAC)
- Martin Moen · Associate Assistant Deputy Minister, Global Affairs Canada (GAC)
- Rodrigo Arancibia · Director General, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Gaby Bourbara · In-house (corporation)
- Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
and 6 moreShow fewer
- Annahat Kochar · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Sara O'Connor · AADM, Regulatory Operations and Enforcement Brach, Health Canada (HC)
- Celia Lourenco · AADM, Health Products and Food Branch, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
-
Reported by Gaby Bourbara · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director General, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
-
Reported by Gaby Bourbara · In-house (corporation)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more
-
Reported by Gaby Bourbara · In-house (corporation)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
-
Reported by Gaby Bourbara · In-house (corporation)
- Maggie Chi · Member of Parliament
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Annahat Kochar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
and 7 moreShow fewer
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.